Skip to Content

'
Padmanee Sharma, MD, PhD

Present Title & Affiliation

Primary Appointment

Member, Investigational Drug Steering Committee (IDSC) for the National Cancer Institute’s Clinical Trials Working Group, Chelsea, MI
Scientific Director Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Member, The University of Texas Graduate School of Biomedical Sciences Faculty, Houston, TX
Director, Flow Cytometry Facility in Koch Center of GU Medical Oncology, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
Department of Genitourinary Medical Oncology
1515 Holcombe
Unit Number: Unit 18-7
Houston, TX 77030
Email: padsharma@mdanderson.org

Education & Training

Degree-Granting Education

1998 Pennsylvania State University, College of Medicine, Hershey, PA, MD, Medicine
1998 Pennsylvania State University, College of Medicine, Hershey, PA, Ph.D., Immunology
1991 Boston University, Boston, MA, MA, Biotechnology
1990 Boston University, Boston, MA, BA, Biology

Postgraduate Training

6/2004 Clinical Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
6/2000 Clinical Residency, Internal Medicine, New York Hospital, Cornell Medical Center, New York, NY

Board Certifications

1/2003 Board Certified Medical Oncology
1/2000 Board Certified Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005-2010
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2004-2010
Fellow, Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, 7/2000-7/2004
Resident, New York Hospital, Cornell Medical Center, New York, NY, 7/1998-7/2000

Other Appointments/Responsibilities

Member, Executive Committee, Clinical Immunology Society, Milwaukee, WI, 2012-2015
Member, ASCO Scientific Program Committee on the Developmental Therapeutics-Clinical Pharmacology and Immunotherapy Track, Alexandria, VA, 2010-present
Board Member, Society for Immunotherapy of Cancer, Milwaukee, WI, 2010-present
Member, Cancer Research Institute Cancer Vaccine Acceleration Fund (CVAF) Global Sourcing Committee, New York, NY, 2010-present
Member, Stand Up to Cancer (SU2C) Innovative Research Grants (IRG) Scientific Review Committee, Philadelphia, PA, 2010
Associate Clinical Director, Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center, New York, NY, 7/2007-11/2012

Honors and Awards

2012 MD Anderson Cancer Center Faculty Scholar Award
2012 MD Anderson Women Faculty Programs "Woman Leading the Way"
2012 National Institute of Health R01 Award
2011 Cancer Prevention Research Institute of Texas Award
2010 DOD/CDMRP Idea Development Award
2009 American Cancer Society Mentored Research Scholar Grant
2008 Doris Duke Clinical Scientist Development Award
2008 Melanoma Research Alliance Young Investigator Award
2008 Prostate Cancer Foundation Challenge Award in Immunology
2007 Carl C. Anderson, Sr. & Marie Jo Anderson Charitable Foundation
2007 MD Anderson Cancer Center Bladder Cancer SPORE Development Award
2007 The Gillson Longenbaugh Foundation
2006 American Society of Clinical Oncology Career Development Award
2006 Cancer Research Institute Clinical Investigator Award
2006 Prostate Cancer Foundation Young Investigator Award
2005 MD Anderson Cancer Center Institutional Research Grant
2005 MD Anderson Cancer Center Physician Scientist Training Program Award
2005 National Institute of Health Renewal Clinical Loan Repayment Program Award
2003 American Society of Clinical Oncology, Young Investigator Award Recipient
2003 Award Recipient, GSK National Medical Oncology Fellows Forum
2002 Award for Abstract Presentation, Doris Duke Symposium
2001 Memorial Sloan-Kettering Cancer Center Institutional NIH T32 Grant
1998 Pennsylvania State University, Department of Medicine Scholarship for Excellence in Medicine
1995 Pennsylvania State University Student Clinician Research Award
1994 The Judy S. Finkelstein Memorial Award in Immunology
1990 Golden Key National Honor Society

Professional Memberships

American Association for Cancer Research (AACR)
Member, 2006-present
American Society of Clinical Oncology (ASCO)
Member, 2005-present
Anti-CTLA Clinical Trials, LICR/CRI/BMS Initiative
Member, 2006
ASCO Scientific Program Committee on the Developmental Therapeutics-Clinical Pharmacology and Immunotherapy Track
Member, 2011-present
Cancer Research Institute Cancer Vaccine Acceleration Fund (CVAF) Global Sourcing Committee
Member, 2010-present
Clinical Immunology Society, Milwaukee, IL
Councilor, 2012-2015
International Society for Biological Therapy of Cancer (iSBTc)
Member, Board of Directors, 2010
Member, 2005-present
International Society for Biological Therapy of Cancer Organizational Collaborations (now known as Society for Immunotherapy of Cancer, SITC)
Member, 2010
Investigational Drug Steering Committee (IDSC) Task Force
Member, 2012-present
SITC Program Committee
Member, 2010
SITC Strategic Planning Retreat
Member, 2010
Stand Up to Cancer (SU2C) Innovative Research Grants (IRG) Scientific Review Committee
Member, 2010-present
Women in Cancer Research (AACR), Philadelphia, PA
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Richey SL, Tamboli P, NG CS, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of Pemetrexed plus Gemcitabine in patients with locally advanced and metastatic non-clear cell renal cell carcinoma. Am J Clin Oncol, 6/2012. PMID: 22706175.
2. Sun JJ, Ng Tang D, Fu T,Sharma P. Identification of human regulatory T cells in the setting of T cell activation and anti-CTLA-4 immunotherapy based on expression of latency associated peptide (LAP). Cancer Discovery 2(2):122-30, 2012. PMID: 22585857.
3. Fox BA, Schendel DJ, Butterfield LH. . Sharma P, etal. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 9(1):214, 12/2011. PMCID: PMC3338100.
4. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal anti-tumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71(16):5445-54, 8/2011. PMID: 21708958.
5. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 5/2010. PMCID: PMC2919850.
6. Matin SF, Sharma P, Gill IS, Tannenbaum C, Hobart MG, Novick AC, Finke JH. Immunologic response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 183(1):333-8, 1/2010. PMID: 19914660.
7. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15(6):2130-9, 3/2009. PMID: 19276258.
8. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-{gamma} levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2/2009. PMCID: PMC2650334.
9. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 31(9):849-57, 11/2008. PMID: 18833002.
10. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi T cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 9/2008. PMCID: PMC2567480.
11. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9, 5/2008. PMCID: PMC2935772.
12. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104(49):19458-63, 12/2007. PMCID: PMC2148311.
13. Kopetz S, Jimenez CA, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Resp J 29(4):813-5, 4/2007. PMID: 17400880.
14. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967-72, 3/2007. PMCID: PMC1820692.
15. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442-7, 9/2006. PMID: 17000678.
16. Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Old LJ. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T cell epitope in a patient with bladder cancer. Cancer Immun 3:19, 12/2003. PMID: 14680360.
17. Sharma P, Page MJ, Poritz LS, Koltun WA, Chorney MJ. An increased gamma delta T cell population in the intestine of thymus-leukemia antigen transgenic mice. Cell Immunol 176(2):153-7, 3/1997. PMID: 9073388.
18. Sharma P, Johnson CA, Bonneau RH, Lang CM, Chorney MJ. Transgenic mice expressing the thymus leukemia antigen fail to control cutaneous herpes simplex virus infection. Cell Immunol 174(1):84-9, 11/1996. PMID: 8929457.
19. Joyce S, Negishi I, Boestanu A, DeSilva DA, Sharma P , Chorney MJ, Loh DY, Van Kaer L. Expansion of natural (NK1+) T cells that express alpha/beta T-cell receptors in transporters associated with antigen presentation-1 null and thymus-leukemia antigen positive mice. J Exp Med 184(4):1579-84, 10/1996. PMCID: PMC2192848.
20. Venditti CP, Lawlor DA, Sharma P, Chorney MJ. Structure and content of the major histocompatibility complex (MHC) class I regions of the great anthropoid apes. H Immunol 49(2):71-84, 9/1996. PMID: 8872161.
21. Sharma P, Joyce S, Chorney K, Griffith J, Bonneau RH, Wilson F, Flavell R, Chorney MJ. Thymus-leukemia antigen, T18d, interacts with T cells and self peptides. J Immunol 156(3):987-96, 2/1996. PMID: 8558026.

Invited Articles
1. Gao JJ, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 34(2):90-8, 2/2013. PMCID: PMC3565019.
2. Lizee G, Overwij WW, Radvanyi L, Gao JJ, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annual Rev Med 64(71-90), 2013. e-Pub 10/2012. PMID: 23092383.
3. Sharma P, Logothetis C. Prostate cancer: Combination of vaccine plus ipilimumab-safety and toxicity. Nat Rev Urol 9(6):302-3, 5/2012. e-Pub 2012. PMID: 22565371.
4. Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science 335(6064):49, 1/2012. PMID: 22223799.
5. Gerritsen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: A focus on immunotherapy. Journal of Clinical Immunology 32(1):25-35, 11/2011. PMCID: PMC3276755.
6. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nature Reviews Cancer 11(11):805-12, 10/2011. PMCID: PMC3426440.
7. Hammeerstrom A, Cauley D, Atkinson B, Sharma P. Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy 31(8):813-28, 8/2011. PMID: 21923608.
8. Sharma P. Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host. Proc Natl Acad Sci U S A 107(32):13977-8, 8/2010. PMCID: PMC2922614.
9. Mittendorf EA, Sharma P. Mechanisms of T cell inhibition: Implications for cancer immunotherapy. Expert Rev Vaccines 9(1):89-105, 1/2010. PMID: 20021308.
10. Carthon B, Sharma P. Advanced urothelial carcinoma: Current treatment strategies and novel agents in clinical trials. CML Urology 14:57-68, 2009. PMID: 20460488.
11. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2009.
12. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in bladder cancer. Cancer Immun 7:10, 6/2007. PMCID: PMC2935746.
13. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high risk bladder cancer. Semin Oncol 34(2):165-72, 4/2007. PMID: 17382800.
14. Pagliaro LC, Sharma P. Review of treatment strategies for metastatic bladder cancer. Minerva Urol Nefrol 58:53-71, 2006. PMID: 16760884.
15. Sharma P, Donat MS, Herr H, Bajorin D. Treatment of locally advanced bladder cancer. Princ Prac Oncol Updates 16:8, 2001.

Abstracts
1. Aparicio A, Sun JJ, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Sharma P. A Phase II Study of Ipilimumab Plus Androgen Deprivation Therapy in Castration-sensitive Prostate Carcinoma. American Association for Clinical Research, 2012.
2. Gao JJ, Sun J, Ward J, Rao P, Troncoso P, Araujo J, Ng Tang D, Chen H, Thall P, Wen S, Sharma P. Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer. American Association for Cancer Research, 2012.
3. Bajorin DF, Sharma P, Sims RB, Sandler A, Lerner SP. Design of a Phase 2 randomized, open-label trial of DN24-02, an autologous cellular immunotherapy trgeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. American Society of Clinical Oncology, 2012.
4. Gao JJ, Chen H, Ng Tang D, Sharma P. Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. American Society of Clinical Oncology, 2012.
5. Sharma P. Investigating the role of the ICOS/ICOSL pathway in mediating anti-tumor responses in the setting of CTLA-4 blockade. Penn State College of Medicine, Penn State Hershey Cancer Institute, 2012.
6. Sharma P. Novel Approaches to Assessing T-Cell Function and Reactivity. ASCO 2012 Markers in Cancer, 2012.
7. Sharma P. Anti-CTLA-4 therapy requires the ICOS/ICOSL pathway to mediate optimal anti-tumor responses. Center for Immune Modulatory Therapies for Autoimmunity and Cancer, Karolinska Institutet, Ljusterö, Sweden, 2011.
8. Sharma P. CTLA-4 and ICOS as Cancer Immunotherapy Targets. American Association for Cancer Research,, 2011.
9. Sharma P. Immune monitoring of CTLA-4 blockade on a pre-surgical clinical trial: Implicating the ICOS/ICOSL pathway in anti-tumor immune responses. Hematology and Medical Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, 2011.
10. Sharma P. Immunologic Consequences of Renal Ablation and Rationale for Combination Renal Ablation/Immunomodulation Strategies. MD Anderson Cancer Center Kidney Multidisciplinary Research Program, 2011.
11. Sharma P. Immunology: From Bench to Bedside and Back. Translational Science: From Bench to Bedside and Back, MD Anderson Cancer Center Deaprtment of Investigational Cancer Therapeutics, 2011.
12. Sharma P. Implicating the ICOS/ICOSL Pathway as a Target for Cancer Immunotherapy. Clinical Immunology Society, 2011.
13. Sharma P. Investigating the ICOS/ICOSL pathway as a target to improve anti-tumor responses mediated by CTLA-4 blockade. Translational Research Seminar, Mt. Sinai School of Medicine, 2011.
14. Sharma P. Management of Metastatic Clear Cell RCC (1) Immunotherapeutic Approaches, Old and New. MD Anderson Cancer Center Department of Genitourinary Medical Oncology Courses on Renal Cell Carcinoma, 2011.
15. Sharma P. Novel agents and targets in immunotherapy. First Annual Kidney Cancer Collaborative Symposium, MD Anderson Cancer Center Kidney Multidisciplinary Research Program, 2011.
16. Sharma P. Assessment of biologic impact of immunotherapeutic agents. American Association for Cancer Research, 2010.
17. Sharma P. Defining the Role of Inducible Co-stimulator (ICOS)-Expressing T Cells Against Melanoma. Melanoma Research Association, 2010.
18. Sharma P. Immune monitoring of CTLA-4 blockade on a pre-surgical clinical trial: Implicating the ICOS/ICOSL pathway in anti-tumor immune responses. American Association for Cancer Research - Tumor Immunology, 2010.
19. Sharma P. Monitoring Immune and Clinical Responses to Anti-CTLA-4 Therapy. University of Connecticut Center for Immunotherapy of Cancer and Infectious Diseases, Health Center Seminar Series, 2010.
20. Sharma P. Pre-operative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Canadian Society of Immunology, 2010.
21. Sharma P. Pre-operative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Department of Immunology Seminar, Ontario Cancer Institute, Princess Margaret Hospital, 2010.
22. Sharma P. Pre-surgical Clinical Trials in Cancer Patients to Identify Biomarkers of Immunotherapy. Clinical Immunology Society, 2010.
23. Sharma P. Prostate Cancer Immunotherapy: Immune Responses Mediated by CTLA-4 Blockade. Free University Amsterdam Prostate Cancer Symposium, 2010.
24. Sharma P. Role of ICOS-expressing T Cells in Anti-tumor Responses Mediated by CTLA-4 Blockade. Basic Science Distinguished Lecturer Program, Washington University School of Medicine, 2010.
25. Sharma P. Assessment of Biologic Impact of Immunotherapeutic Agents. American Association for Cancer Research Molecular Biology Clinical Oncology Workshop, 2009.
26. Sharma P. Immune responses mediated by CTLA-4 blockade. ABCAM Immune Tolerance in Cancer and Autoimmune Disease Conference, 2009.
27. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. Melanoma Research Alliance Annual Meeting, 2009.
28. Sharma P. Immunize Responses Mediated by CTLA-4 Blockade. Keystone Symposia: Mobilizing Cellular Immunity for Cancer Therapy, 2009.
29. Sharma P. Immunologic Impact of Anti CTLA-4 Therapy. American Association for Cancer Research Annual Meeting, 2009.
30. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. American Society of Clinical Oncology Annual Meeting, 2009.
31. Sharma P. Is there Still a Role for Immunotherapy in the Treatment of Metastatic Renal Cell Carcinoma. MD Anderson Cancer Center - Urology Oncology Conference, 2009.
32. Sharma P. Systemic Chemotherapy for Urothelial Carcinoma. MD Anderson Cancer Center 9th Annual Oncology Update: Advances and Controversies, 2009.
33. Sharma P. Functional and Phenotypic Impact of Anti-CTLA-4 Antibody in the Pre-surgical Setting. American Association for Cancer Research Annual Meeting, 2008.
34. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. American Association for Cancer Research Annual Meeting, Plenary Session, 2008.
35. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. Cancer Research Institute Annual Meeting, 2008.
36. Sharma P. Immunotherapy for Renal Cell Carcinoma. MD Anderson Cancer Center, 2008.
37. Sharma P. Immunology Impact of Anti-CTLA-4 Antibody in a Neoadjuvant Setting. Cancer Research Institute Annual Meeting, 2007.
38. Sharma P. Immunotherapy for Prostate Cancer. Prostate Cancer Foundation Annual Meeting, 2007.
39. Sharma P. Monitoring Immune Response in Patients Treated with Immunotherapy, Physician-Scientist/Clinician Investigator Update. MD Anderson Cancer Center Pioneers Group, 2007.
40. Sharma P. Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma Patients. MD Anderson Cancer Center Genitourinary Medical Oncology Bladder SPORE, 2007.
41. Sharma P. CD8+ Tumor-Infiltrating Lymphocytes as a Statistically Significant Marker of Disease Recurrence and Survival in Transitional Cell Carcinoma Patients. American Society of Clinical Oncology Annual Meeting, 2006.
42. Sharma P. Immunological Studies in Prostate Cancer. MD Anderson Cancer Center - Center for Cancer Immunology, 2006.
43. Sharma P. Regulatory T-cells Are Increased in the Tumor Microenvironment of Prostate Cancer Patients. Cancer Research Institute Annual Meeting, 2006.
44. Sharma P. Combinatorial Targeting of the NY-ESO-1 Cancer Testis Antigen. Cancer Research Institute Annual Meeting, 2005.
45. Sharma P. Protein and DNA-based Vaccines With NY-ESO-1 Antigen in Cancer Patients. International Society for Biological Therapy of Cancer Annual Meeting, 2005.
46. Sharma P. Protein and DNA-based Vaccines with the NY-ESO-1 Antigen in Cancer Patients. National Cancer Institute Center of Excellence in Immunology, 2005.

Book Chapters
1. Callahan MK, Wolchok JD, Allison JP, Sharma P. Immune Co-signaling to Treat Cancer. In: Cancer Immunotherapy: Paradigms, Practice and Potential. Springer: NewYork. In Press.
2. Peggs KS, Quezada SA, Sharma P, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition, 2010. ISBN: 978-1-607-950-141.

Grant & Contract Support

Title: Immunologic Checkpoint Blockade and Adoptive Cell transfer in Cancer Therapy
Funding Source: AACR-CRI - SU2C Immunology
Role: Investigator
Duration: 3/1/2013 - 2/28/2016
 
Title: Targeting the ICOS/ICOSL pathway to Improve Anti-tumor Immune Responses
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/12/2012 - 5/31/2017
 
Title: Combining local ablationi plus systemic immunotherapy to improve anti-tumor responses in renal cell carcinoma
Funding Source: MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program
Role: Co-Investigator
Principal Investigator: Matin
Duration: 2/1/2012 - 1/31/2013
 
Title: Improving on Anti-CTLA-4 Therapy
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 12/1/2011 - 11/30/2014
 
Title: ICOS-expressing T Cells as Mediators of Antitumor Immune Responses
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 2/1/2010 - 2/28/2013
 
Title: CTLA-4 Blockade in Therapy of Prostate Cancer
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2009 - 6/30/2013
 
Title: M. D. Anderson Cancer Center Prostate SPORE - Immunologic Effect of Anti-CTLA-4 Therapy on Prostate Cancer (CL 30924)
Funding Source: NIH/NCI
Role: DRPA
Principal Investigator: C. Logothetis
Duration: 2/9/2009 - 8/31/2011
 
Title: Blockade of CTLA-4 to Induce Effective Anti-tumor Immune Responses in Cancer Patients
Funding Source: Doris Duke Charitable Foundation
Role: Principal Investigator
Duration: 10/1/2008 - 9/30/2012
 
Title: CTLA-4 Blockade in Therapy of Prostate Cancer: Therapeutic Mechanisms and New Directions
Funding Source: Prostate Cancer Foundation Challenge Award
Role: Co-Investigator
Duration: 10/1/2008 - 9/30/2012
 
Title: Defining the Role of ICOS-expressing T Cells Against Melanoma
Funding Source: Melanoma Research Alliance Young Investigators Award
Role: Principal Investigator
Duration: 9/1/2008 - 10/31/2011
 
Title: Characterizing Immunological Responses for Correlation with Clinical Outcome in Prostate Cancer Patients Treated with Anti-CTLA-4 Therapy in the Neoadjuvant Setting
Funding Source: Prostate Cancer Foundation Young Investigator Award
Role: Principal Investigator
Duration: 10/10/2007 - 11/14/2009
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: The Gillson Longenbaugh Foundation
Role: Principal Investigator
Duration: 9/1/2007 - 8/31/2010
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: Carl C. Anderson Sr. & Marie Jo Anderson Charitable Foundation
Role: Principal Investigator
Duration: 9/2007 - 8/2010
 
Title: Enhancing Immune Responses Against Bladder Cancer
Funding Source: The Gillson Longenbaugh Foundation
Role: Principal Investigator
Duration: 8/2007 - 8/2010
 
Title: Effector and Regulatory T cell Responses in Prostate Cancer Patients
Funding Source: Cancer Research Institute Clinical Investigator Grant
Role: Principal Investigator
Duration: 2/1/2007 - 12/31/2011
 
Title: Determining Regulatory T-Cell Influences on Effector T-Cell Function in Prostate Cancer Patients
Funding Source: The University of Texas MD Anderson Cancer Center Institutional Research Grant
Role: Principal Investigator
Duration: 1/26/2007 - 1/26/2008
 
Title: Identification and Correlation of Immune Responses and Tumor Responses in Transitional Cell Carcinoma Patients Treated with Immunotherapy Agents
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/2006 - 6/2009
 
Title: Identification and Correlation of Immune Responses and Tumor Responses in Transitional Cell Carcinoma Patients Treated with NY-ESO-1 Vaccine
Funding Source: The University of Texas MD Anderson Cancer Center Physician Scientist Training Program Award
Role: Principal Investigator
Duration: 9/1/2005 - 9/1/2011
 
Title: Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/2005 - 8/2006
 
Title: Targeting NY-ESO-1 and Other Novel Tumor Antigens for Cancer Immunity
Funding Source: The University of Texas MD Anderson Cancer Center Shooting Down Cancer Institutional Research Grant
Role: Principal Investigator
Duration: 8/23/2005 - 8/23/2006

Last updated: 5/1/2013